Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biomerica (BMRA) EBITDA Margin (2016 - 2026)

Biomerica's EBITDA Margin history spans 17 years, with the latest figure at 132.93% for Q1 2026.

  • On a quarterly basis, EBITDA Margin fell 2891.0% to 132.93% in Q1 2026 year-over-year; TTM through Feb 2026 was 96.28%, a 1067.0% decrease, with the full-year FY2025 number at 93.69%, up 1656.0% from a year prior.
  • EBITDA Margin hit 132.93% in Q1 2026 for Biomerica, down from 109.17% in the prior quarter.
  • Over the last five years, EBITDA Margin for BMRA hit a ceiling of 0.29% in Q3 2025 and a floor of 205.07% in Q2 2025.
  • Historically, EBITDA Margin has averaged 102.59% across 5 years, with a median of 109.17% in 2025.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 12888bps in 2022 and later crashed -14847bps in 2023.
  • Tracing BMRA's EBITDA Margin over 5 years: stood at 110.32% in 2022, then grew by 13bps to 96.17% in 2023, then surged by 39bps to 58.31% in 2024, then tumbled by -87bps to 109.17% in 2025, then dropped by -22bps to 132.93% in 2026.
  • Business Quant data shows EBITDA Margin for BMRA at 132.93% in Q1 2026, 109.17% in Q4 2025, and 0.29% in Q3 2025.